At 7.2% CAGR, the Europe Fish Vaccines Market is Projected to be worth US$ 191.33 million by 2030, says Business Market Insights

According to Business Market Insights research, the Europe fish vaccines market was valued at US$ 110.00 million in 2022 and is expected to reach US$ 191.33 million by 2030, registering a CAGR of 7.2% from 2022 to 2030. Government initiatives to develop aquaculture industry and surging demand for aquatic animal-derived food products are the critical factors attributed to the Europe fish vaccines market expansion.

Emergence of disease outbreak caused by parasites, viruses, and bacteria have slowed down the evolution of the global aquaculture industry for several decades. Aside from being harmful to human health, emerging diseases have a significant impact on aquatic animals. Traditional vaccines have limitations and drawbacks, which bolsters the demand for the development of novel advanced vaccines such as chimeric multiepitope vaccines. Newer avenues in the basic and applied research fields of aquatic vaccines have been opened up by scientific and technological advancements. An effort has been made to create novel aquatic vaccines with higher quality and efficiency using new technologies, approaches, and strategies. Using the available bioinformatics tools and current knowledge of immunoproteomics and genomics, researchers can identify potential targeted epitopes that immune cells can recognize. Further, as the cost of techniques such as whole genome sequencing continues to decline, it opens the way for species-specific vaccine development. This is likely to boost investments in developing new vaccines. Thus, the development of an effective mucosal vaccine with strengthening the administration process is expected to accelerate the novel vaccine development, which would boost the aquaculture businesses in Mediterranean countries to regularize fish vaccination processes. Hence, development of novel fish vaccines is likely creating significant opportunity for market growth.

On the contrary, stringent regulations for approval of vaccine hurdles the growth of Europe fish vaccines market.

Based on vaccine type, the Europe fish vaccines market is categorized into inactivated vaccines, live attenuated vaccines, subunit vaccines, recombinant vector vaccine, and others. The inactivated vaccines segment held 72.0% market share in 2022, amassing US$ 79.22 million. It is projected to garner US$ 139.76 million by 2030 to expand at 7.4% CAGR during 2022-2030.

Based on application, the Europe fish vaccines market is categorized into bacterial infection, viral infection, and parasitic. The bacterial infection segment held 80.8% share of Europe fish vaccines market in 2022, amassing US$ 88.88 million. It is projected to garner US$ 156.26 million by 2030 to expand at 7.3% CAGR during 2022-2030.

Based on route of administration, the Europe fish vaccines market is categorized into injection vaccine, immersion vaccine, and oral vaccine. The injection vaccine segment held 59.8% share of Europe fish vaccines market in 2022, amassing US$ 65.74 million. It is projected to garner US$ 113.72 million by 2030 to expand at 7.1% CAGR during 2022-2030.

Based on species, the Europe fish vaccines market is categorized into salmon, trout, tilapia, and others. The salmon segment held 71.8% share of Europe fish vaccines market in 2022, amassing US$ 78.98 million. It is projected to garner US$ 135.99 million by 2030 to expand at 7.0% CAGR during 2022-2030.

Based on country, the Europe fish vaccines market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that the UK captured 28.8% share of Europe fish vaccines market in 2022. It was assessed at US$ 31.66 million in 2022 and is likely to hit US$ 56.59 million by 2030, exhibiting a CAGR of 7.5% during 2022-2030.

Key players operating in the Europe fish vaccines market are Elanco Animal Health Inc, Hipra SA, Merck & Co Inc., Phibro Animal Health Corp, Vaxxinova International BV, and Zoetis Inc., among others.

- In Aug 2020, Elanco Closes Acquisition of Bayer Animal Health.

- In Mar 2020, HIPRA and Skretting combine expertise to tackle devasting trout disease.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com